X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://endpts.com/incyte-stops-phiii-trial-for-pi3k-inhibitor-after-primary-endpoint-failure/
https://www.reuters.com/business/healthcare-pharmaceuticals/incyte-discontinue-late-stage-trial-bone-marrow-cancer-drug-combination-2023-03-03/
https://www.prnewswire.com/news-releases/innovent-announces-the-national-medical-products-administration-in-china-has-accepted-and-granted-priority-review-designation-to-the-new-drug-application-for-parsaclisib-pi3k-inhibitor-for-the-treatment-of-relapsed-or-refractor-301715196.html
https://www.fiercebiotech.com/biotech/incyte-pulls-fda-filing-for-cancer-drug-approval-over-confirmatory-study-following-gilead
https://www.asiaone.com/business/innovent-announces-pivotal-phase-2-results-parsaclisib-pi3k-inhibitor-presented-ash-2021
https://investor.incyte.com/press-releases/press-releases/2021/Incyte-Announces-Acceptance-of-NDA-for-Parsaclisib-for-Three-Types-of-Relapsed-or-Refractory-Non-Hodgkin-Lymphomas/default.aspx
https://www.prnewswire.com/news-releases/innovent-announces-parsaclisib-treatment-results-in-high-rate-of-rapid-and-durable-responses-in-patients-with-relapsed-or-refractory-b-cell-non-hodgkin-lymphomas-301187349.html
https://www.prnewswire.com/news-releases/innovent-announces-first-patient-dosed-in-a-pivotal-trial-of-parsaclisib-in-patients-with-indolent-lymphoma-in-china-301047392.html
https://seekingalpha.com/article/4230259-incyte-scores-lucrative-deal-3-pipeline-products
https://www.prnewswire.com/news-releases/innovent-and-incyte-announce-strategic-collaboration-and-licensing-agreement-for-three-clinical-stage-product-candidates-in-china-300767163.html
Market Place
Share 
